NEW YORK (GenomeWeb News) – Tegal said after the close of the market yesterday that it has received approval from its shareholders to change the name of the firm to CollabRx.
The name change comes a couple of months after Tegal completed its purchase of genomics data analysis firm CollabRx for an undisclosed amount. At the time, Tegal had said that it would ask its shareholders to approve the name change.
As of tomorrow, the firm's shares will trade on the Nasdaq under the ticker symbol CLRX.
Tegal develops new and emerging technologies with a current focus on technologies in the medical device and healthcare segments. CollabRx offers cloud-based systems to inform healthcare decision-making using genomics-based medicine.
Each firm's CEO — Thomas Mika of Tegal and James Karis of CollabRx — are serving as co-CEOs of the San Francisco-based firm. Mika continues to serve as chairman.